Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome Hirotoshi IiharaHironori FujiiAkio Suzuki Original Article Open access 18 December 2018 Pages: 393 - 398
Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells Yu Hua QuanJi-Young LimHyun Koo Kim Original Article 04 December 2018 Pages: 399 - 410
A phase II trial of the effect of perindopril on hand–foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC Barbara L. MeloskyHoward John LimDaniel John Renouf Original Article Open access 08 December 2018 Pages: 411 - 417
Randomized phase II trial of the prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in Capeox (YCOG1205) Yusuke SuwaJun WatanabeItaru Endo Original Article 06 December 2018 Pages: 419 - 424
Severe hypersensitivity reactions to platinum compounds post-pressurized intraperitoneal aerosol chemotherapy (PIPAC): first literature report Matthieu SiebertMohammad AlyamiVahan Kepenekian Original Article 03 December 2018 Pages: 425 - 430
Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study Gabriella FerrandinaGiacomo CorradoGiovanni Scambia Original Article 01 December 2018 Pages: 431 - 438
Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma Da-xiong ZengWei LeiJun-hong Jiang Original Article 13 December 2018 Pages: 439 - 442
A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas Xuyan LiuMingzi YangWeiping Liu Original Article 03 December 2018 Pages: 443 - 449
Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells Sadhna AggarwalSarah JohnSatya N. Das Original Article 05 December 2018 Pages: 451 - 461
Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study Naveed ShaikBrian HeeRobert R. LaBadie Original Article Open access 10 December 2018 Pages: 463 - 472
A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer Linda R. DuskaGina R. PetroniSarah J. Parsons Original Article 08 December 2018 Pages: 473 - 482
Evaluation of the effects of an oral notch inhibitor, crenigacestat (LY3039478), on QT interval, and bioavailability studies conducted in healthy subjects Eunice YuenMaria PosadaJeffrey Suico Original Article 11 December 2018 Pages: 483 - 492
Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms Milena GusellaFelice PasiniRoberto Padrini Original Article 12 December 2018 Pages: 493 - 500
Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer Sung Yong OhSuee LeeHoUng Kim Original Article 08 December 2018 Pages: 501 - 508
Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers Chunhua WangChaoying HuLan Zhang Original Article 10 December 2018 Pages: 509 - 517
Anti-liver cancer effect and the mechanism of arsenic sulfide in vitro and in vivo Shudan WangChao ZhangChaoying Li Original Article 12 December 2018 Pages: 519 - 530
Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model Kate R. SecombeImogen A. BallJoanne M. Bowen Original Article 10 December 2018 Pages: 531 - 543
Increase in cetuximab-induced skin rash and hypomagnesemia in patients receiving concomitant treatment with proton pump inhibitors (PPIs): a possible drug interaction? Mahmoud Abu-AmnaGil Bar-Sela Original Article 13 December 2018 Pages: 545 - 550
Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors Ravi PaluriAnkit MadanFrancisco Robert Original Article 02 January 2019 Pages: 551 - 559
The value of serum cystatin C in early evaluation of renal insufficiency in patients undergoing chemotherapy: a systematic review and meta-analysis Liyun HeJine LiWenxiong Zhang Original Article 04 January 2019 Pages: 561 - 571
A successful compartmental approach for the treatment of breast cancer brain metastases Thuy T. NguyenEurydice AngeliGuilhem Bousquet Original Article 05 January 2019 Pages: 573 - 580
Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma Ken SasakiYasuto UchikadoShoji Natsugoe Original Article 08 January 2019 Pages: 581 - 587
A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity Mihaela C. CristeaPaul FrankelRobert J. Morgan Original Article 08 January 2019 Pages: 589 - 598
Inflammatory bowel disease associated with the combination treatment of nivolumab and metformin: data from the FDA adverse event reporting system Huaqiang ZhouJiaqing LiuLi Zhang Short Communication 08 January 2019 Pages: 599 - 601
